+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "Dupilumab"

Nasal Polyps Treatment Market Report 2025 - Product Thumbnail Image

Nasal Polyps Treatment Market Report 2025

  • Report
  • February 2025
  • 200 Pages
  • Global
From
Skin Allergy Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Skin Allergy Therapeutics - Global Strategic Business Report

  • Report
  • March 2025
  • 89 Pages
  • Global
From
Rhinitis - Pipeline Insight, 2024 - Product Thumbnail Image

Rhinitis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 90 Pages
  • Global
From
From
Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024 - Product Thumbnail Image

Chronic Obstructive Pulmonary Disease - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 220 Pages
  • Global
From
Food Allergy - Pipeline Insight, 2024 - Product Thumbnail Image

Food Allergy - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
Sinusitis - Pipeline Insight, 2024 - Product Thumbnail Image

Sinusitis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 80 Pages
  • Global
From
Sinusitis Pipeline Insight Analysis Report - Product Thumbnail Image

Sinusitis Pipeline Insight Analysis Report

  • Drug Pipelines
  • August 2024
  • 150 Pages
  • Global
From
From
Dupilumab Emerging Drug Insight and Market Forecast - 2032 - Product Thumbnail Image

Dupilumab Emerging Drug Insight and Market Forecast - 2032

  • Report
  • November 2023
  • 30 Pages
  • Global
From
From
From
  • 18 Results (Page 1 of 1)
Loading Indicator

Dupilumab is a monoclonal antibody used to treat respiratory diseases such as asthma and chronic obstructive pulmonary disease (COPD). It works by blocking the action of a protein called interleukin-4 (IL-4) and interleukin-13 (IL-13), which are involved in inflammation. Dupilumab is approved for use in adults and adolescents aged 12 years and older with moderate-to-severe asthma, and for adults with moderate-to-severe COPD. It is administered as an injection under the skin. Dupilumab is a relatively new drug, and is the first biologic therapy approved for the treatment of asthma and COPD. It has been shown to reduce symptoms and improve lung function in patients with these conditions. It is also being studied for use in other respiratory diseases, such as eosinophilic asthma and bronchiolitis obliterans syndrome. Some companies in the Dupilumab market include Regeneron Pharmaceuticals, Sanofi, and AstraZeneca. Show Less Read more